SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (252)8/5/2003 11:27:31 AM
From: Jim Oravetz  Read Replies (2) of 278
 
Myriad Genetics comments on Alzheimer's disease candidate drug (MYGN) 14.55: Co announces that its Alzheimer's disease candidate drug, MPC-7869 (R-flurbiprofen) reduces levels of Abeta42 more effectively than any other compound tested, according to a new study. Abeta42 is the primary constituent of senile plaques that accumulate in the brains of patients with Alzheimer's disease.

Briefing.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News